April 16, 2018 Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago
April 12, 2018 Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
April 11, 2018 Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion